CREDENCE – more evidence of benefits with SGLT2 inhibitors – write to your MLA
Today (2019-Apr-15) the results of the much anticipated CREDENCE study which examined the benefits of canagliflozin (a member of the SGLT2 inhibitor class) were presented in Melbourne, Australia. Striking benefits were shown for individuals with Type 2 diabetes-related kidney disease including a 30% reduction in progression of kidney disease, 20% reduction in cardiovascular death/heart attack/stroke […]